Skip to main content
Log in

Counterweight-Plus controls T2DM at low cost

  • Clinical study
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Notes

  1. 2016/2017 British pounds

Reference

  • Xin Y, et al. Type 2 diabetes remission: economic evaluation of the DiRECT/Counterweight-Plus weight management programme within a primary care randomized controlled trial. Diabetic Medicine : 26 Apr 2019. Available from: URL: http://doi.org/10.1111/dme.13981

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Counterweight-Plus controls T2DM at low cost. PharmacoEcon Outcomes News 828, 11 (2019). https://doi.org/10.1007/s40274-019-5885-7

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-019-5885-7

Navigation